Bisphosphonate-Generated ATP-Analogs Inhibit Cell Signaling Pathways

Area of Science:

• Biochemistry
• Pharmacology
• Medicinal Chemistry

Background:

• Bisphosphonates are crucial therapeutics for osteoporosis, Paget's disease, and cancer.
• Proposed mechanisms of action include inhibition of protein prenylation, EGFR, or adenine nucleotide translocase.
• Adenine nucleotide translocase inhibition involves cellular formation of ATP analogs like ApppI and AppCCl2p.

Purpose of the Study:

• To investigate the kinase inhibition profiles of bisphosphonate-derived ATP analogs.
• To explore the potential of bisphosphonate preprodrugs as novel kinase inhibitors.
• To elucidate the molecular interactions underlying bisphosphonate-mediated kinase inhibition.

Main Methods:

• Screening of ApppI and AMP-clodronate (AppCCl2p) against a panel of 369 kinases.
• Synthesis and cellular evaluation of bisphosphonate preprodrugs.
• Analysis of kinase inhibition and cellular signaling pathway modulation.

Main Results:

• AppCCl2p demonstrated potent inhibition of certain tyrosine kinases, attributed to hydrogen bonding with tyrosine residues.
• Synthesized bisphosphonate preprodrugs were converted intracellularly to ATP analogs.
• These novel analogs acted as low nanomolar kinase inhibitors, effectively suppressing cellular signaling pathways.

Conclusions:

• The findings clarify the mechanism of action for bisphosphonates as kinase inhibitors.
• Bisphosphonate preprodrugs represent a promising strategy for developing new therapeutic agents.
• This research opens avenues for novel drug leads targeting bone resorption, cancer, and inflammation.